Chemotherapy with low-dose bevacizumab and carboplatin in the treatment of a patient with recurrent cervical cancer

European Journal of Gynaecological Oncology

Volumn 31, Issue 3, 2010, Pages 350-353

  Tan, S J ^a   Juan, Y H ^a   Fu, P T ^a   Yu, M H ^a   Lai, H C ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Bevacizumab; Cervical cancer; Metronomic

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; VALPROIC ACID;

ADULT; ADVANCED CANCER; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BONE BIOPSY; BRACHYTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STAGING; CASE REPORT; CHEMOSENSITIZATION; COMPUTER ASSISTED TOMOGRAPHY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; ISCHIALGIA; LAMINECTOMY; LEUKOPENIA; LOW BACK PAIN; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; PAPANICOLAOU TEST; RADIATION DOSE; RADICAL HYSTERECTOMY; RECURRENT DISEASE; SPINE DISEASE; SPINE METASTASIS; SPINE STABILIZATION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CONIZATION;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARBOPLATIN; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; UTERINE CERVICAL NEOPLASMS;

EID: 77954124424     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. World Health Organization. Comprehensive cervical cancer control: a guide to essential practice. Geneva. Switzerland: World Health Organization, 2006.
2. Benedet J.L., Odicino F., Maisonneuve P., Beller U., Creasman W.T., Heintz A.P. et al.: "Carcinoma of the cervix uteri". Int. J. Gynaecol. Obstet., 2003, 83 (suppl. 1), 41.
3. Bonomi P., Blessing J.A., Stehman F.B., DiSaia P.J., Walton L., Major F.J.: "Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study". J. Clin. Oncol., 1985, 3, 1079. (Pubitemid 15004828)
4. Green J.A., Kirwan J.M., Tierney J.F., Symonds P., Fresco L., Collingwood M. et al.: "Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis". Lancet, 2001, 358 (9284), 781.
5. Tao X., Hu W., Ramirez P.T., Kavanagh J.J.: "Chemotherapy for recurrent and metastatic cervical cancer". Gynecol. Oncol., 2008, 110 (3 suppl. 2), S67.
6. Folkman J.: "What is the evidence that tumors are angiogenesis dependent?". J. Natl. Cancer Inst., 1990, 82, 4.
7. Shin T., Lindley C.: "Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies". Clin. Ther., 2006, 28, 1779.
8. Rasila K.K., Burger R.A., Smith H., Lee F.C., Verschraegen C.: "Angiogenesis in gynecological oncology-mechanism of tumor progression and therapeutic targets". Int. J. Gynecol. Cancer, 2005, 15, 710. (Pubitemid 41783074)
9. Weiss G.R., Green S., Hannigan E.V., Boutselis J.G., Surwit E.A., Wallace D.L. et al.: "A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group study". Gynecol. Oncol., 1990, 39, 332.
10. rd, Bundy B.N., Grendys E.C. Jr, Benda J.A., McMeekin D.S., Sorosky J. et al.: "Randomized phase II trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study". J. Clin. Oncol., 2005, 23, 4626.
11. Lee I.J., Park K.R., Lee K.K., Lee K.K., Song J.S., Lee K.G. et al.: "Prognostic value of vascular endothelial growth factor in Stage IB carcinoma of the uterine cervix". Int. J. Radiat. Oncol. Biol. Phys., 2002, 54, 768.
12. Wright J.D., Viviano D., Powell M.A., Gibb R.K., Mutch D.G., Grigsby P.W. et al.: "Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer". Gynecol. Oncol., 2006, 103, 489. (Pubitemid 44602157)
13. Monk B.J., Sill M.W., Burger R.A., Gray H.J., Buekers T.E., Roman L.D.: "Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study". J. Clin. Oncol., 2009, 27, 1069.
14. Willett C.G., Boucher Y., di Tomaso E., Duda D.G., Munn L.L., Tong R.T. et al.: "Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer". Nat. Med., 2004, 70, 145.
15. Spannuth W.A., Sood A.K., Coleman R.L.: "Angiogenesis as a strategic target for ovarian cancer therapy". Nat. Clin. Pract. Oncol., 2008, 5, 194.